Trial Outcomes & Findings for Implantation With the Nucleus CI532 Cochlear Implant in Adults (NCT NCT02677220)

NCT ID: NCT02677220

Last Updated: 2019-03-12

Results Overview

The AzBio Sentence test was recorded at 3 months prior to subject withdraw. Not collected at endpoint. AzBio Tests consists of 15 lists of 20 sentences each. AzBio sentences are spoken by different talkers in a conversational style with limited contextual cues that the listener can use to predict or 'fill in' unintelligible words. Each list includes 5 sentences from 4 different male and female speakers. Each word in the sentence counts toward the overall score and the resulting score is presented in percent correct.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

1 participants

Primary outcome timeframe

3 months post-activation

Results posted on

2019-03-12

Participant Flow

Participant milestones

Participant milestones
Measure
Surgical
Subjects implanted with the CI532 cochlear implant in one ear
Overall Study
STARTED
1
Overall Study
COMPLETED
0
Overall Study
NOT COMPLETED
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Surgical
Subjects implanted with the CI532 cochlear implant in one ear
Overall Study
Adverse Event
1

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Surgical
n=1 Participants
Subjects implanted with the CI532 cochlear implant in one ear
Age, Continuous
63 years
STANDARD_DEVIATION 0 • n=1 Participants
Sex: Female, Male
Female
0 Participants
n=1 Participants
Sex: Female, Male
Male
1 Participants
n=1 Participants

PRIMARY outcome

Timeframe: 3 months post-activation

The AzBio Sentence test was recorded at 3 months prior to subject withdraw. Not collected at endpoint. AzBio Tests consists of 15 lists of 20 sentences each. AzBio sentences are spoken by different talkers in a conversational style with limited contextual cues that the listener can use to predict or 'fill in' unintelligible words. Each list includes 5 sentences from 4 different male and female speakers. Each word in the sentence counts toward the overall score and the resulting score is presented in percent correct.

Outcome measures

Outcome measures
Measure
Surgical
n=1 Participants
Subjects implanted with the CI532 cochlear implant in one ear
AzBio Sentence Recognition in Noise
35 percent correct
Standard Deviation 0

SECONDARY outcome

Timeframe: 6 months post-activation

Population: subject did not reach endpoint - GBI was not collected at 3 months per protocol

The Glasgow Benefit Inventory (GBI) is a health utility assessment used at six months post-operatively. Performance benefits are a change in score from pre- to post-operatively, scored from -100 to +100.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 months post-activation

Population: subject did not reach endpoint - SSQ was not collected at 3 months per protocol

The Speech Spatial and Qualities of Hearing Scale (SSQ) is a subjective measure of satisfaction. Change is reflected in a gain in scores pre- to post-operatively (-10 to +10).

Outcome measures

Outcome data not reported

Adverse Events

Surgical

Serious events: 1 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Surgical
n=1 participants at risk
Subjects with the CI532 cochlear implant in one ear
Ear and labyrinth disorders
Device Explant
100.0%
1/1 • 8 months
SAE October 2016 - blood and pus draining from the incision. Antibiotics prescribed. November 2016 - resolved. Initial activation of the device. December 2016 through April 26, 2017 - continued drainage and treatment using a combination of routine wound care and oral antibiotics. June 2017 - Explantation required July 2017 - Withdrawn - test device was no longer in place.

Other adverse events

Adverse event data not reported

Additional Information

Director of Clinical Research

Cochlear

Phone: 3032647180

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place